1.Clinical trial of nifedipine controlled-release tablets in the treatment of elderly isolated systolic hypertension
Shi-Qiang WANG ; Yang-Zhang TANG ; Huai-Jin ZHANG ; Liu-Qiang L(U) ; You-Ji ZHANG ; Li ZHAO
The Chinese Journal of Clinical Pharmacology 2017;33(14):1298-1300
Objective To compare the clinical efficacy and safety of nifedipine controlled-release tablets and felodipine sustained release tablets in the treatment of elderly isolated systolic hypertension.Methods A total of 76 elderly patients with isolated systolic hypertension were randomly divided into control group and treatment group with 38 cases per group.Control group was given felodipine sustained release tablets 5 rag,qd,oral.Treatment group was given nifedipine controlled-release tablets 30 mg,qd,oral.Two groups were treated for 6 weeks.The clinical efficacy,blood pressure and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates in treatment and control groups were 92.11% (35/38 cases) and 73.68% (28/38 cases).The systolic blood pressure in treatment and control groups were (129.28 ± 13.02),(136.35 ± 14.09) mmHg,with significant difference (P < 0.05).The adverse drug reactions in treatment group were dizziness and edema,which in control group were dizziness,edema and rash.The incidences of adverse drug reactions in treatment and control groups were 5.26% and 7.89%,without significant difference (P > 0.05).Conclusion Nifedipine controlled-release tablets had a definitive clinical efficacy in the treatment of isolated systolic hypertension in the elderly,which are better than felodipine sustained release tablets,without increasing the incidence of adverse drug reactions.
2.Fasudil inhibits platelet-derived growth factor-induced human pulmonary artery smooth muscle cell proliferation by up-regulation of p27kip1 via the ERK signal pathway
Ai-Jun LIU ; Feng LING ; Dong WANG ; Qiang WANG ; Xiao-Dong L(U) ; Ying-Long LIU
Chinese Medical Journal 2011;125(19):3098-3104
Background RhoA/ Rho kinase (ROCK) pathway is involved in pulmonary arterial hypertension (PAH) and pulmonary artery smooth muscle cell (PASMC) proliferation. Inhibition of ROCK has been proposed as a treatment for PAH. But the mechanism of RhoA/ROCK pathway and its downstream signaling in proliferation of human PASMCs is unclear. We investigated the effect of fasudil, a selective ROCK inhibitor, on platelet-derived growth factor (PDGF) induced human PASMC proliferation, and the possible association between RhoA/ROCK and extracellular signal-regulated kinase (ERK),p27KiP1.Methods Human PASMCs were cultured with the stimulation of 10 ng/ml PDGF, and different concentrations of fasudil were added before the addition of mitogen. Cell viability and cell cycle were determined with MTT and flow cytometry respectively. ROCK activity, ERK activity and protein expression of proliferating cell nuclear angigen (PCNA) and p27Kip1 were measured by immunoblotting.Results By MTT assay, PDGF significantly increased the OD value that represented human PASMC proliferation, and pretreatment with fasudil significantly reversed this effect in a dose-dependent manner. After PDGF stimulation, the percentage of cells in S phase increased dramatically from 15.6% to 24.3%, while the percentage in G0/G1 phase was reduced from 80.6% to 59%. And pretreatment with fasudil reversed the cell cycle effect of PDGF significantly in a dose-dependent manner. PDGF markedly induced ROCK activity and ERK activity with a peak at 15 minutes, which were significantly inhibited by fasudil. In addition, fasudil significantly inhibited PDGF-induced PCNA expression and fasudil also upregulated p27Kip1 expression in human PASMCs, which decreased after PDGF stimulation.Conclusion RhoA/ROCK is vital for PDFG-induced human PASMC proliferation, and fasudil effectively inhibited PDGF-induced human PASMC proliferation by up-regulation of p27Kip1, which may be associated with inhibition of ERK activity.
3.Intravenous transplantation of mesenchymal stem cells attenuates oleic acid induced acute lung injury in rats
Yu-Lin XU ; Ying-Long LIU ; Qiang WANG ; Gang LI ; Xiao-Dong L(U) ; Bo KONG
Chinese Medical Journal 2012;(11):2012-2018
Background Acute lung injury (ALI) and end-stage acute respiratory distress syndrome (ARDS) were among the most common causes of death in intensive care units.The activation of an inflammatory response and the damage of pulmonary epithelium and endotheliumwerethe hallmark of ALI/ARDS.Recent studies had demonstrated the importance of mesenchymal stem cells (MSCs) in maintaining the normal pulmonary endothelial and epithelial function as well as participating in modulating the inflammatory response and they are involved in epithelial and endothelial repair after injury.Here,our study demonstrates MSCs therapeutic potential in a rat model of ALI/ARDS.Methods Bone marrow derived MSCs were obtained from Sprague-Dawley (SD) rats and their differential potential was verified.ALl was induced in rats byoleic acid (OA),and MSCs were transplanted intravenously.The lung injury and the concentration of cytokines in plasma and lung tissue extracts were assessed at 8 hours,24 hours and 48 hours after OA-injection.Results The histological appearance and water content in rat lung tissue were significantly improved at different time points in rats treated with MSCs.The concentration of tumor necrosis factor-α and intercellular adhesion molecular-1 in rats plasma and lung tissue extracts were significantly inhibited after intravenous transplantation of MSCs,whereas interleukin-10 was significantly higher after MSCs transplantation at 8 hours,24 hours and 48 hours after OA-challenge.Conclusions Intravenous transplantation of MSCs could maintain the integrity of the pulmonary alveolar-capillary barrier and modulate the inflammatory response to attenuate the experimental ALI/ARDS.Transplantation of MSCs could be a novel cell-based therapeutic strategy for prevention and treatment of ALI/ARDS.
4.Status quo and factors influencing smoking cessation in cigarette smoking patients with coronary artery disease
Tai-Yang LUO ; Tao LEI ; Xiao-Hui LIU ; Xue-Mei PENG ; Jun-Ping KANG ; Qiang L(U) ; Hai-Yun WANG ; Chang-Sheng MA
Chinese Journal of Cardiology 2011;39(5):406-409
Objective To investigate the status quo of smoking cessation and analyze factors influencing smoking cessation in cigarette smoking patients with coronary artery disease(CAD).Method A total of 350 smoking patients with CAD was surveyed by questionnaire,logistic regression analysis was performed to analyze factors influencing smoking cessation.Results Incidence of smoking cessation was 57.1%(200/350)in this cohort.Patients were divided into two groups,the elderlv(>65 years old,n=111)and the young group(≤65 years old,n=239).The smoking cessation rate in the elderlv group is significantly higher than in the young group(71.2%vs.50.6%,P<0.001).Aged patients and patients with high cultural level are easier to give up smoking.Logistic analysis showed that age≤65 years old (OR=2.336,P=0.004),low cultural level(OR=1.310,P=0.028),PCI(OR=0.261.P<0.001).coronary artery bypass graft(OR=0.107,P=0.004),total family income>4000 RMB/month (OR=1.828,P=0.003)are risk factors for failed smoking cessation.There are 76 patients smoking again in current smokers,most due to lack of self-control(76.3%).Compared to the elderly group,there is a higher proportion of smoking again due to the need of daily communication and work in the young group.Conclusions We still need to raise the awareness of smoking cessation for smoking patients with CAD.Following factors should be focused for tobacco control in CAD patients:younger age,lower cuItural level,not treated with PCI or CABG,patients with smoking family members.higher body mass index and higher total family income.
5.Investigation of lipid metabolism disorder in maintenance hemodialysis patients and its influencing factors
Li WANG ; Jian GAO ; Bo SHEN ; Xiao-Qiang DING ; Wen-Lü L(U) ; Xue-Sen CAO ; Zhong-Hua LIU ; Jie TENG ; Jian-Zhou ZOU
Chinese Journal of Clinical Medicine 2017;24(5):705-709
Objective:To investigate the lipid levels of maintenance hemodialysis (MHD) patients from single center and to explore the related risk factors.Methods:MHD patients (dialysis duration >3 months) in blood purification center of Zhongshan Hospital,Fudan University were enrolled in the research.Fasting blood lipid including triglyceride (TG),total cholesterol (TC),high density lipoprotein cholesterol (HDL-C),low density lipoprotein cholesterol (LDL-C),glycosylated hemoglobin (HbA1c),serum albumin and other indicators were tested,and dialysis adequacy evaluation was made.At the same time,patients' general information and medical history were collected.Results:The average levels of TC,TG,HDL-C and LDL-C in 203 patients were (4.45 ± 1.16) mmol/L,(1.93 ± 2.18) mmol/L,(1.16 ± 0.34) mmol/L,(2.51 ± 0.93) mmol/L,respectively.132 patients (65%) were bothered by lipid abnormalities.Proportions of serum high TC and LDL-C abnormality were higher in women than in men while low HDL-C abnormality proportion was lower in women than in men (P<0.05).Serum TG level was higher in patients over 60 years old than those under 45 years old and among 45-59 years old (P<0.05).However,patients under 45 years old had the highest prevalence of dyslipidemia (P<0.05).Patients with dialysis duration >60 months had lower proportion of TG abnormality than patients with duration <12 months and among 12 60 months (P<0.05).Prevalence of dyslipidemia was highest in the group with duration <12 months (P<0.05).Serum TG level was lower in patients with HbA1c≤6% than in patients with HbA1c>6% (P<O.05). Higher prevalence of dyslipidemia occurred in patients with HbA1c>6% (P<O.05).Conclusions: Lipid metabolism disorder is common among MHD patients.Female, dialysis duration<12 months, younger than 45years old, and HbA1c>6% are risk factors of lipid metabolism abnormality in such patients.
6.Haemostatic agents of the gelatin matrix for a large liver wound by percutaneous injection without pressure under the guidance of contrast-enhanced ultrasound
Teng-Fei YU ; Fa-Qin L(U) ; Zhi-Yan LI ; Ling LIU ; Qiang LIU ; Ai-Jun LIU ; Ya-Qin HUANG ; Jie TANG
Chinese Medical Journal 2011;(9):1352-1356
Background The non-operation treatment of intra-abdominal trauma guided contrast enhanced ultrasound (CEUS) is one of the hottest research topic. Gelatin/thrombin/calcium (GTC) was developed as a novel haemostatic agent for non-operable intra-abdominal trauma. We hypothesized that GTC can achieve haemostasis (without the use of pressure)within a short time in a large wound model by percutaneous injection under CEUS guidance.Methods Forty Wister rats received large liver injuries by haemostatic clamp and were randomly divided into four groups, according to the haemostatic agent used. These included normal saline (NS) group A, lyophilising thrombin powder (LTP) group B, GTC group C, and absorbable α-cyanoacrylate (ACNA) group D. Each injury site was treated with one of the above materials and total bleeding time was recorded. All liver wounds were evaluated using CEUS at three periods: pre-injury, injury and post-treatment. The liver wounds were also evaluated by histology 3, 6, and 9 days after injury and the extents of abdominal adhesions were recorded.Results The sensitivity of CEUS (100%) in detecting blunt traumatic liver lesions was significantly higher than conventional ultrasound (42.5%). Bleeding times at the injury site in the GTC group C ((129.3±14.0) seconds) and ACNA group D ((5.2±1.0) seconds) were significantly shorter than those in the NS group A ((369.5±48.8) seconds, P <0.01) and LTP group B ((324.7±52.22) seconds, P <0.01). The LTP group B showed no significant difference compared with the NS group A. Gross examination of liver tissue revealed that there were fewer intra-abdominal adhesions in the GTC group C (10%) than in the ACNA group D (100%). Histopathologic examination showed that GTC was completely absorbed after nine days.Conclusions GTC, delivered by percutaneous injection under CEUS, may achieve haemostasis (without the use of pressure) within a short time in a large wound model. GTC is absorbable and may prevent intra-abdominal adhesions.Therefore, it may be the optimal choice for first aid treatment of large abdominal wounds in the setting of blunt trauma.
7.External Quality Analysis of Quality Indicators on Specimen Acceptability
Yuan-Yuan YE ; Wei WANG ; Hai-Jian ZHAO ; Feng-Feng KANG ; Wei-Xing LI ; Zhi-Ming LU ; Wei-Min ZOU ; Yu-Qi JIN ; Wen-Fang HUANG ; Bin XU ; Fa-Lin CHEN ; Qing-Tao WANG ; Hua NIU ; Bin-Guo MA ; Jian-Hong ZHAO ; Xiang-Yang ZHOU ; Zuo-Jun SHEN ; Wei-Ping ZHU ; Yue-Feng L(U) ; Liang-Jun LIU ; Lin ZHANG ; Li-Qiang WEI ; Xiao-Mei GUI ; Yan-Qiu HAN ; Jian XU ; Lian-Hua WEI ; Pu LIAO ; Xiang-Ren A ; Hua-Liang WANG ; Zhao-Xia ZHANG ; Hao-Yu WU ; Sheng-Miao FU ; Wen-Hua PU ; Lin PENG ; Zhi-Guo WANG
Journal of Modern Laboratory Medicine 2018;33(2):134-138,142
Objective To analyze the status of quality indicators(QI) on specimen acceptability and establish preliminary qual ity specification.Methods Web based External Quality Assessment system was used to collect data of laboratories partici pated in "Medical quality control indicators in clinical laboratory" from 2015 to 2017,including once in 2015 and 2017 and twice in 2016.Rate and sigma scales were used to evaluate incorrect sample type,incorrect sample container,incorrect fill level and anticoagulant sample clotted.The 25th percentile (P25) and 75th percentile (P75) of the distribution of each QI were employed to establish the high,medium and low specification.Results 5 346,7 593,5 950 and 6 874 laboratories sub mitted the survey results respectively.The P50 of biochemistry (except incorrect fill level),immunology and microbiology reach to 6σ.The P50 of clinical laboratory is 4 to 6σ except for incorrect sample container.There is no significant change of the continuous survey results.Based on results in 2017 to establish the quality specification,the P25 and P75 of the four QIs is 0 and 0.084 4 %,0 and 0.047 6 %,0 and 0.114 2 %,0 and 0.078 4 %,respectively.Conclusion According to the results of the survey,most laboratories had a faire performance in biochemistry,immunology and microbiology,and clinical laboratory needs to be strengthened.Laboratories should strengthen the laboratory information system construction to ensure the actual and reliable data collection,and make a long time monitoring to achieve a better quality.